Thlaspi arvense suppresses gut microbiota related TNF inflammatory pathway to alleviates ulcerative colitis DOI Creative Commons
Wenkai Wang, Yiyang Zhao, Ziwei Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 22, 2025

Thlaspi arvense (TA), commonly known as "Ximi" or "Subaijiang," is a traditional Chinese medicinal herb used to prevent and treat ulcerative colitis (UC). However, the precise mechanisms underlying its therapeutic effects remain unclear, necessitating further investigation identify potential pharmaceutical applications for UC management. This study aims elucidate efficacy of TA active constituents in treatment. first evaluated varying doses on 3% dextran sulfate sodium (DSS)-induced UC. Gut microbiota alterations mice were analyzed via 16S rRNA sequencing, with correlation analyses reveal relationship between gut cytokines. Then, network pharmacology was utilized identified targets Protein-protein interaction (PPI) networks, Gene Ontology (GO), Kyoto Encyclopedia Genes Genomes (KEGG) enrichment employed explore TA's mechanisms. Molecular docking dynamics simulations validated interactions compounds UC-related targets. Finally, TNF pathway modulation by component, isovitexin, verified vitro vivo. alleviated DSS-induced weight loss dose-dependent manner, reduced disease activity indices, preserved intestinal mucosal barrier integrity. Subsequently, fluorescence situ hybridization (FISH) revealed suppressed microbial translocation tissues. To characterize inflammatory responses, ELISA demonstrated that modulated levels key cytokines (TNF-α, IL-1β, IL-6, IL-10) oxidative stress markers (SOD, MDA), indicating systemic anti-inflammatory effects. Building these findings, sequencing showed regulated alpha/beta diversity inhibited infectious disease-related pathways. Notably, heatmaps highlighted strong association TNF-α Escherichia-Shigella abundance, high-dose significantly reducing this pathogenic bacterial genus. systematically molecular mechanisms, 220 Consistent experimental data, PPI KEGG implicated TNF-α, AKT targets, primarily through signaling modulation. validate predictions, confirmed stable while specifically emphasized isovitexin's high affinity TNF-α. experiments vivo inhibition TNF-α-mediated NF-κB activation, studies isovitexin directly mitigated TNF-α-induced epithelial damage. Furthermore, potent activation tissues, constituent effectively cell damage, collectively highlighting their complementary Collectively, (TA) ameliorates synergistic involving modulation, suppression, preservation. By remodeling communities reduce colonization translocation. concurrently inhibits TNF-α/NF-κB-driven inflammation, regulation. attenuates demonstrating multi-scale efficacy. These findings establish multi-target spanning host-microbe intracellular signaling, providing rationale standardizing TA-based formulations advancing precision agent bowel diseases.

Язык: Английский

An update ont the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis DOI
A. Zimmer,

Gerd Horneff

Expert Opinion on Drug Safety, Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

An increasing number of patients with polyarticular course juvenile idiopathic arthrtitis are treated biologics great efficacy. Consequently, the importance regarding safety data in general as well especially serious infections, incident autoimmune processes, or malignancies rises. In children, this is crucial concerning occurrences that manifest rarely and only after a prolonged latency period. This study aims to analyze under therapy five most commonly used biologicals for treatment arthritis Germany: abatacept, adalimumab, etanercept, golimumab tocilizumab, control cohort, who received methotrexate. For this, from Biologics Pediatric Rheumatology (BiKeR) Registry were analyzed focus on potential adverse drug reactions like prozesses malignancies. Besides JIA category-specific differences, investigating side effects severe infections development additional processes due crucial. Future clinical randomized double-blinded studies essential direct comparisons, enabling optimal individualized considering comorbidities individual risks. Large patient over (life-)long period beyond childhood particularly important, risk malignancy latency.

Язык: Английский

Процитировано

0
Biobetters and biosimilars in Inflammatory Bowel Disease DOI

Jacopo Fanizza,

Ilaria Faggiani,

Mariangela Allocca

и другие.

Best Practice & Research Clinical Gastroenterology, Год журнала: 2025, Номер unknown, С. 101992 - 101992

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Gut virome and its implications in the pathogenesis and therapeutics of inflammatory bowel disease DOI Creative Commons

Yushan Wu,

Rui Cheng, Hao Lin

и другие.

BMC Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Март 26, 2025

Язык: Английский

Процитировано

0
Thlaspi arvense suppresses gut microbiota related TNF inflammatory pathway to alleviates ulcerative colitis DOI Creative Commons
Wenkai Wang, Yiyang Zhao, Ziwei Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 22, 2025

Thlaspi arvense (TA), commonly known as "Ximi" or "Subaijiang," is a traditional Chinese medicinal herb used to prevent and treat ulcerative colitis (UC). However, the precise mechanisms underlying its therapeutic effects remain unclear, necessitating further investigation identify potential pharmaceutical applications for UC management. This study aims elucidate efficacy of TA active constituents in treatment. first evaluated varying doses on 3% dextran sulfate sodium (DSS)-induced UC. Gut microbiota alterations mice were analyzed via 16S rRNA sequencing, with correlation analyses reveal relationship between gut cytokines. Then, network pharmacology was utilized identified targets Protein-protein interaction (PPI) networks, Gene Ontology (GO), Kyoto Encyclopedia Genes Genomes (KEGG) enrichment employed explore TA's mechanisms. Molecular docking dynamics simulations validated interactions compounds UC-related targets. Finally, TNF pathway modulation by component, isovitexin, verified vitro vivo. alleviated DSS-induced weight loss dose-dependent manner, reduced disease activity indices, preserved intestinal mucosal barrier integrity. Subsequently, fluorescence situ hybridization (FISH) revealed suppressed microbial translocation tissues. To characterize inflammatory responses, ELISA demonstrated that modulated levels key cytokines (TNF-α, IL-1β, IL-6, IL-10) oxidative stress markers (SOD, MDA), indicating systemic anti-inflammatory effects. Building these findings, sequencing showed regulated alpha/beta diversity inhibited infectious disease-related pathways. Notably, heatmaps highlighted strong association TNF-α Escherichia-Shigella abundance, high-dose significantly reducing this pathogenic bacterial genus. systematically molecular mechanisms, 220 Consistent experimental data, PPI KEGG implicated TNF-α, AKT targets, primarily through signaling modulation. validate predictions, confirmed stable while specifically emphasized isovitexin's high affinity TNF-α. experiments vivo inhibition TNF-α-mediated NF-κB activation, studies isovitexin directly mitigated TNF-α-induced epithelial damage. Furthermore, potent activation tissues, constituent effectively cell damage, collectively highlighting their complementary Collectively, (TA) ameliorates synergistic involving modulation, suppression, preservation. By remodeling communities reduce colonization translocation. concurrently inhibits TNF-α/NF-κB-driven inflammation, regulation. attenuates demonstrating multi-scale efficacy. These findings establish multi-target spanning host-microbe intracellular signaling, providing rationale standardizing TA-based formulations advancing precision agent bowel diseases.

Язык: Английский

Процитировано

0